ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
نویسندگان
چکیده
منابع مشابه
Reasons for treating secondary AML as de novo AML.
In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-rela...
متن کاملSplicing factor mutations in AML.
heralds a new era of targeted therapies for the management of this disease. The drug is generally well tolerated with mostly mild side effects that frequently resolve despite continuation of therapy. The responses observed are primarily sustained partial responses with occasional complete responses, which appear to be independent of conventional prognostic markers. Similar results were also see...
متن کاملReason for CPXcitement in AML.
http://bloodjournal.hematologylibrary.org/content/123/21/3211.full.html Updated information and services can be found at: (2500 articles) Free Research Articles Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be fo...
متن کاملPoint mutations in the FLT3 gene in AML.
In 1969, a forgettable Hollywood movie parodied the information overload that tourists experience when they visit several countries in the shortest time possible. Thirty years later, scientists who are interested in chemokines also find their heads spinning in response to a seemingly endless and rapid parade of newly discovered chemokines and receptors. In this issue, Struyf and colleagues (pag...
متن کاملClinical implications of FLT3 mutations in pediatric AML.
Activating mutations of the FLT3 gene occur because of an internal tandem duplication of the juxta-membrane domain (FLT3/ITD) or point mutation of the activation loop domain (FLT3/ALM). The presence of FLT3 mutations as well as the allelic ratio of FLT3/ITD (ITD-AR, mutant-wild type ratio) may have prognostic significance. FLT3 mutation status of 630 children with de novo acute myeloid leukemia...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v124.21.2343.2343